These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 11925283)

  • 1. Ondansetron in the treatment of cognitive decline in Alzheimer dementia.
    Dysken M; Kuskowski M; Love S;
    Am J Geriatr Psychiatry; 2002; 10(2):212-5. PubMed ID: 11925283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A preliminary randomized, double-blind, placebo-controlled study of the safety and efficacy of ondansetron in the treatment of cocaine dependence.
    Johnson BA; Roache JD; Ait-Daoud N; Javors MA; Harrison JM; Elkashef A; Mojsiak J; Li SH; Bloch DA
    Drug Alcohol Depend; 2006 Oct; 84(3):256-63. PubMed ID: 16631323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A preliminary randomized, double-blind, placebo-controlled study of the safety and efficacy of ondansetron in the treatment of methamphetamine dependence.
    Johnson BA; Ait-Daoud N; Elkashef AM; Smith EV; Kahn R; Vocci F; Li SH; Bloch DA;
    Int J Neuropsychopharmacol; 2008 Feb; 11(1):1-14. PubMed ID: 17470315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Added ondansetron for stable schizophrenia: a double blind, placebo controlled trial.
    Akhondzadeh S; Mohammadi N; Noroozian M; Karamghadiri N; Ghoreishi A; Jamshidi AH; Forghani S
    Schizophr Res; 2009 Feb; 107(2-3):206-12. PubMed ID: 18789844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of decreasing afferent vagal activity with ondansetron on symptoms of bulimia nervosa: a randomised, double-blind trial.
    Faris PL; Kim SW; Meller WH; Goodale RL; Oakman SA; Hofbauer RD; Marshall AM; Daughters RS; Banerjee-Stevens D; Eckert ED; Hartman BK
    Lancet; 2000 Mar; 355(9206):792-7. PubMed ID: 10711927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial.
    Wilkinson D; Windfeld K; Colding-Jørgensen E
    Lancet Neurol; 2014 Nov; 13(11):1092-1099. PubMed ID: 25297016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ondansetron and simvastatin added to treatment as usual in patients with schizophrenia: study protocol for a randomized controlled trial.
    Chaudhry IB; Husain N; Husain MO; Hallak J; Drake R; Kazmi A; Rahman Ru; Hamirani MM; Kiran T; Mehmood N; Stirling J; Dunn G; Deakin B
    Trials; 2013 Apr; 14():101. PubMed ID: 23782463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A double-blind, placebo-controlled pilot study of ondansetron for patients with obsessive-compulsive disorder.
    Soltani F; Sayyah M; Feizy F; Malayeri A; Siahpoosh A; Motlagh I
    Hum Psychopharmacol; 2010 Aug; 25(6):509-13. PubMed ID: 20737524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of ondansetron in the treatment of generalized anxiety disorder.
    Freeman AM; Westphal JR; Norris GT; Roggero BA; Webb PB; Freeman KL; Rush JA; Hearne EM; Evoniuk G
    Depress Anxiety; 1997; 5(3):140-1. PubMed ID: 9323456
    [No Abstract]   [Full Text] [Related]  

  • 10. A randomized, controlled crossover trial of ondansetron in patients with primary biliary cirrhosis and fatigue.
    Theal JJ; Toosi MN; Girlan L; Heslegrave RJ; Huet PM; Burak KW; Swain M; Tomlinson GA; Heathcote EJ
    Hepatology; 2005 Jun; 41(6):1305-12. PubMed ID: 15915460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: A randomized controlled trial.
    Johnson BA; Roache JD; Javors MA; DiClemente CC; Cloninger CR; Prihoda TJ; Bordnick PS; Ait-Daoud N; Hensler J
    JAMA; 2000 Aug 23-30; 284(8):963-71. PubMed ID: 10944641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment trial of oxiracetam in Alzheimer's disease.
    Green RC; Goldstein FC; Auchus AP; Presley R; Clark WS; Van Tuyl L; Green J; Hersch SM; Karp HR
    Arch Neurol; 1992 Nov; 49(11):1135-6. PubMed ID: 1444879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective, open-label trial of ondansetron in adolescents with alcohol dependence.
    Dawes MA; Johnson BA; Ait-Daoud N; Ma JZ; Cornelius JR
    Addict Behav; 2005 Jul; 30(6):1077-85. PubMed ID: 15925118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of ondansetron on postoperative delirium and cognitive function in aged orthopedic patients.
    Papadopoulos G; Pouangare M; Papathanakos G; Arnaoutoglou E; Petrou A; Tzimas P
    Minerva Anestesiol; 2014 Apr; 80(4):444-51. PubMed ID: 24193238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metoclopramide versus ondansetron for the treatment of vomiting in children with acute gastroenteritis.
    Al-Ansari K; Alomary S; Abdulateef H; Alshawagfa M; Kamal K
    J Pediatr Gastroenterol Nutr; 2011 Aug; 53(2):156-60. PubMed ID: 21788756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study.
    Mohs RC; Shiovitz TM; Tariot PN; Porsteinsson AP; Baker KD; Feldman PD
    Am J Geriatr Psychiatry; 2009 Sep; 17(9):752-9. PubMed ID: 19700948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial.
    Freund-Levi Y; Eriksdotter-Jönhagen M; Cederholm T; Basun H; Faxén-Irving G; Garlind A; Vedin I; Vessby B; Wahlund LO; Palmblad J
    Arch Neurol; 2006 Oct; 63(10):1402-8. PubMed ID: 17030655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study.
    Feldman HH; Ferris S; Winblad B; Sfikas N; Mancione L; He Y; Tekin S; Burns A; Cummings J; del Ser T; Inzitari D; Orgogozo JM; Sauer H; Scheltens P; Scarpini E; Herrmann N; Farlow M; Potkin S; Charles HC; Fox NC; Lane R
    Lancet Neurol; 2007 Jun; 6(6):501-12. PubMed ID: 17509485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Haloperidol versus ondansetron for prophylaxis of postoperative nausea and vomiting.
    Rosow CE; Haspel KL; Smith SE; Grecu L; Bittner EA
    Anesth Analg; 2008 May; 106(5):1407-9, table of contents. PubMed ID: 18420852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of ondansetron in the treatment of schizophrenia.
    Bennett AC; Vila TM
    Ann Pharmacother; 2010; 44(7-8):1301-6. PubMed ID: 20516364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.